JP Morgan Chase
ADMA icon

JP Morgan Chase’s ADMA Biologics ADMA Stock Holding History

JP Morgan Chase’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.86M Buy
+750,000
New +$11.8M ﹤0.01% 3026

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

JP Morgan Chase's ADMA Position: Q1 2026 in Review

JP Morgan Chase increased its ADMA Biologics (ADMA) stake by 72% in Q1 2026, buying an estimated $3.37M and bringing the position to 512,926 shares worth $4.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3374.

JP Morgan Chase first reported a position in ADMA in Q1 2018 and has held it in 32 quarters since. The position peaked at $15.5M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • JP Morgan Chase held 512,926 shares of ADMA Biologics worth $4.69M as of Q1 2026.
  • JP Morgan Chase bought 213,845 ADMA Biologics shares in Q1 2026, an estimated $3.37M.
  • ADMA Biologics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3374 holding.
  • JP Morgan Chase first reported a position in ADMA Biologics in Q1 2018 and has held it in 32 quarters since.
  • JP Morgan Chase's ADMA Biologics position peaked at $15.5M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.